HC Wainwright Comments on Oculis’ Q1 Earnings (NASDAQ:OCS)

Oculis Holding AG (NASDAQ:OCS) – Analysts at HC Wainwright cut their Q1 2026 earnings per share estimates for Oculis in a research note issued on Wednesday, March 4th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($0.47) for the quarter, down from their prior estimate of ($0.46). HC Wainwright has a “Buy” rating and a $44.00 price target on the stock. The consensus estimate for Oculis’ current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Oculis’ Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.50) EPS and FY2026 earnings at ($1.95) EPS.

Oculis (NASDAQ:OCS) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.08). The firm had revenue of $0.50 million during the quarter, compared to analyst estimates of $0.14 million. Oculis had a negative return on equity of 62.12% and a negative net margin of 8,173.41%.

Several other equities research analysts have also issued reports on the stock. Needham & Company LLC lifted their price objective on shares of Oculis from $36.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday. JPMorgan Chase & Co. assumed coverage on Oculis in a research report on Friday, December 19th. They issued an “overweight” rating and a $38.00 price target for the company. Chardan Capital reissued a “buy” rating and set a $51.00 price objective on shares of Oculis in a report on Tuesday, November 11th. Bank of America reduced their target price on Oculis from $30.00 to $29.00 and set a “buy” rating for the company in a report on Thursday, November 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a report on Thursday, January 22nd. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Oculis currently has an average rating of “Moderate Buy” and an average price target of $43.50.

Oculis Trading Up 0.1%

NASDAQ:OCS opened at $27.74 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.47 and a current ratio of 5.96. The company has a market capitalization of $1.45 billion, a P/E ratio of -12.22 and a beta of 0.29. Oculis has a 52 week low of $14.00 and a 52 week high of $30.68. The stock’s 50 day moving average price is $26.03 and its 200 day moving average price is $21.49.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. grew its stake in shares of Oculis by 100.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock worth $40,000 after acquiring an additional 1,000 shares during the last quarter. Aventura Private Wealth LLC bought a new stake in Oculis in the 4th quarter valued at $80,000. Millennium Management LLC bought a new position in shares of Oculis during the 4th quarter worth about $312,000. Bosun Asset Management LLC bought a new position in shares of Oculis during the 2nd quarter worth about $378,000. Finally, Marshall Wace LLP bought a new stake in shares of Oculis in the second quarter valued at about $393,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Oculis

Here are the key news stories impacting Oculis this week:

• Positive Sentiment: Privosegtor received Breakthrough Therapy designation for optic neuritis and Oculis is advancing registrational programs in optic neuropathies — a large addressable U.S. market (>$7B) if trials succeed. This is a material clinical/regulatory positive for OCS. Article Title
• Positive Sentiment: Topline readout for OCS-01 in diabetic macular edema (DIAMOND Phase 3) is on track for Q2 2026 — a near-term binary catalyst that could materially re‑rate the stock if positive. Article Title
• Positive Sentiment: Wall Street support increased: Needham and HC Wainwright raised price targets (to $40 and $44 respectively) and maintain buy ratings — these upgrades can attract investor interest and support higher valuations. Article Title
• Positive Sentiment: Significant institutional accumulation reported (multiple funds added large positions in Q4 2025), which can provide demand support into upcoming catalysts. Article Title
• Neutral Sentiment: Oculis is presenting at multiple investor conferences in March (Leerink Global Healthcare Conference, LifeSci Capital Biotech Forum) — increases management visibility and provides opportunities for Q&A but no direct clinical data. Article Title
• Neutral Sentiment: Company filed audited 2025 consolidated financial statements and MD&A with the SEC — increases transparency; separately, Oculis renewed a $100M ATM program (capital flexibility that can fund development but may dilute if used). Article Title
• Negative Sentiment: Quarterly results missed EPS estimates (reported ($0.51) vs. consensus ($0.43)); while revenue beat estimates, margins and ROE remain deeply negative — a reminder of biotech execution and cash‑burn risk until pivotal approvals. Article Title
• Negative Sentiment: Notifications show RSU vesting/settlement for a director — standard governance activity but adds modest share count pressure/short‑term dilution. Article Title

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.